Clinical Trial Update: Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma [Phase 2, Phase 3]

View source ↗

Summary

This update reports the results of a randomized Phase 2/3 trial comparing ipilimumab and nivolumab with radiation therapy versus the standard temozolomide plus …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma
• Mgmt-unmethylated Glioblastoma

Drugs mentioned

• Temodar (Temozolomide)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Gliosarcoma, MGMT-Unmethylated Glioblastoma | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2024-05-01